---
layout: default
title: Palivizumab
parent: Model Prediction Only (L5)
nav_order: 695
evidence_level: L5
indication_count: 10
---

# Palivizumab
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Palivizumab: From RSV Prevention to Benign Neoplasm of Tongue

## One-Sentence Summary

Palivizumab is a humanized monoclonal antibody against the respiratory syncytial virus (RSV) F protein, marketed in Canada as SYNAGIS.
The TxGNN model predicts it may be effective for **benign neoplasm of tongue**, but **0 clinical trials** and **0 publications** support this prediction.
The high score is a graph-based signal only, and this report found no plausible biological rationale for it.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | RSV prevention (the Canadian license records do not include indication text) |
| Predicted New Indication | Benign neoplasm of tongue |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 2 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the input. Palivizumab is a virus-specific antibody that neutralizes the RSV F protein. Its established use is in RSV-related disease, not in tumours.

No plausible mechanistic link was found between RSV F-protein neutralization and benign tongue tumours. The antibody has no known antiproliferative or immunomodulatory action on benign neoplasms. The score is likely driven by the structure of the knowledge graph rather than by biology.

The same pattern holds across all 10 top-ranked predictions:

- **Disease types:** neoplasms and cysts of the head, neck and other sites, such as epiglottis neoplasm, cervical neuroblastoma, schwannoma of jugular foramen and thyroglossal duct cyst.
- **Scores:** all between 99.93% and 99.94%.
- **Evidence:** none has any clinical trial or literature support, and all are L5.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

| DIN | Product Name |
|---------|------|
| 2438372 | SYNAGIS |
| 2438364 | SYNAGIS |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is supported only by the model score, with no clinical trials, no literature and no plausible mechanistic link. Palivizumab's RSV-specific mechanism does not intersect with tumour biology, so there is no basis for further investment at present.

**To proceed, the following is needed:**
- Mechanism of action data, to allow a formal mechanistic-link analysis
- Health Canada package insert warnings and contraindications, to enable safety screening
- Approved indication text for the two DINs, to confirm the original indication
- Any independent preclinical or clinical evidence linking RSV F-protein antibodies to the predicted disease; without it, the candidate should not advance
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

